Osaic Holdings
MLTX icon

Osaic Holdings’s MoonLake Immunotherapeutics MLTX Stock Holding History

Osaic Holdings’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$296K Buy
15,905
+6,920
+77% +$115K ﹤0.01% 3817
2025
Q4 		$118K Buy
8,985
+8,898
+10,228% +$105K ﹤0.01% 4569
2025
Q3 		$3.05K Buy
87
+37
+74% +$1.93K ﹤0.01% 6996
2025
Q2 		$2.36K Sell
50
-25
-33% -$1.02K ﹤0.01% 6871
2025
Q1 		$2.93K Hold
75
– – ﹤0.01% 6443
2024
Q4 		$4.06K Hold
75
– – ﹤0.01% 6302
2024
Q3 		$3.78K Hold
75
– – ﹤0.01% 6336
2024
Q2 		$3.3K Sell
75
-25
-25% -$1.06K ﹤0.01% 6378
2024
Q1 		$5.02K Sell
100
-1,917
-95% -$104K ﹤0.01% 6090
2023
Q4 		$122K Buy
2,017
+708
+54% +$36.5K ﹤0.01% 4288
2023
Q3 		$74.6K Buy
1,309
+506
+63% +$27.9K ﹤0.01% 4727
2023
Q2 		$41K Buy
803
+727
+957% +$19.6K ﹤0.01% 5067
2023
Q1 		$1.62K Buy
+76
New +$1.28K ﹤0.01% 6797

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Osaic Holdings's MLTX Position: Q1 2026 in Review

Osaic Holdings increased its MoonLake Immunotherapeutics (MLTX) stake by 77% in Q1 2026, buying an estimated $115K and bringing the position to 15,905 shares worth $296K. The position accounts for ﹤0.01% of the portfolio, ranked #3817.

Osaic Holdings first reported a position in MLTX in Q1 2023 and has held it in 13 quarters since. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • Osaic Holdings held 15,905 shares of MoonLake Immunotherapeutics worth $296K as of Q1 2026.
  • Osaic Holdings bought 6,920 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $115K.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Osaic Holdings's portfolio in Q1 2026, its #3817 holding.
  • Osaic Holdings first reported a position in MoonLake Immunotherapeutics in Q1 2023 and has held it in 13 quarters since.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Osaic Holdings's 13F filing for Q1 2026, filed 15 May 2026.